What Longevitytech.fund does

Longevitytech.fund is a venture capital vehicle founded in 2019 and based in Boca Raton, Florida, that invests globally at pre-seed and seed stages in companies developing technologies to extend healthy human lifespan. The fund targets four sub-thematics — therapeutics, platforms & tools, data & AI, and prevention technologies — and positions itself as a specialist in the geroscience category rather than a generalist health investor.

The fund's core infrastructure consists of in-house PhD-level scientific staff supported by a network of more than 100 Key Opinion Leaders across geroscience, biomarkers, and translational medicine, which underwrites its technical diligence. Two proprietary platform companies extend its operational footprint beyond capital provision: HealthyLongevity.clinic, a CRO and human studies operation with centers in Europe and the United States that supports early clinical validation, and HealthyLongevity.Cafe, a consumer testing and engagement layer. As of the data capture, the fund reports $50M+ in assets under management, 35+ portfolio companies across 12 countries, and three successful exits.

The fund's business model follows standard venture fund economics, with revenue derived from management fees on committed AUM and carried interest on portfolio exits. Go-to-market is relationship-driven: deal flow is sourced through direct founder pitch submissions, co-investment syndicates with tier-1 venture partners, and engagement with the in-house KOL network. The fund's primary customer segments are early-stage longevity startups seeking strategic capital, scientific validation infrastructure, and follow-on syndication support, and the limited partners (HNW and institutional) providing capital into a curated, specialist longevity thesis.

Name

Longevitytech.fund

Legal name

LongevityTech.fund

Website

https://longevitytech.fund

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Longevitytech.fund is a Boca Raton-based venture capital fund founded in 2019 that invests globally at pre-seed and seed stages in longevity and healthspan technology startups, supported by in-house PhDs, 100+ KOLs, and proprietary clinical and consumer platform companies.

Ownership category

akta.pro rank

Product category

Longevity Venture Capital / Healthspan Investment Fund

NAICS

Other Investment Pools and Funds (5259)

SIC

Investment Advice (6282)

akta.pro primary industry

Transition / Engagement & Stewardship Funds (FSANAJAO)

Keywords

• Venture capital fund
• Longevity investing
• Healthspan technologies
• Early stage investments
• Biotech venture funding

Headquarters

HQ city

Boca Raton

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Venture Capital Returns: Generating returns through equity investments in early-stage longevity startups. Revenue realized through portfolio company exits, IPOs, and strategic acquisitions. The fund has achieved 3 successful exits as of the data capture date.
2. Management Fees and Carried Interest: Standard venture fund economics including management fees on assets under management and carried interest on profits from successful exits.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Longevitytech.fund is a venture capital fund that invests pre-seed and seed capital in early-stage startups developing technologies that extend healthy human lifespan. The fund focuses on therapeutics, platforms and tools, data and AI, and prevention technologies targeting the root causes of aging. It also operates two proprietary platform companies — HealthyLongevity.clinic (clinical research and CRO services) and HealthyLongevity.Cafe (consumer engagement) — that accelerate translation of portfolio science to products and human markets.

Product overview

LongevityTech.fund operates as a venture capital fund focused on advancing the science and infrastructure of healthspan. The fund deploys patient capital into early-stage longevity companies across therapeutics, platforms & tools, data & AI, and prevention technologies. The fund's unique infrastructure includes two proprietary platform companies—HealthyLongevity.clinic (providing clinical research services and CRO capabilities across Europe and the US) and HealthyLongevity.Cafe (a consumer testing ground and engagement layer)—which together accelerate translation of portfolio companies' technologies to products and human markets. The fund manages $50M+ AUM across a portfolio of 35+ companies, 3 successful exits, and investments spanning 12 countries.

Differentiator

Problem solved

Functional benefit

Brands

• HealthyLongevity.clinic: Platform company providing human studies, CRO services, and clinical validation with centers in Europe and US.
• HealthyLongevity.Cafe

Products and services

• HealthyLongevity.clinic Clinical research platform with centers in Europe and the US that provides human studies, CRO services, and a direct pathway to early clinical validation for longevity technologies developed by portfolio companies and partners.
• HealthyLongevity.Cafe Consumer testing ground and engagement layer that interfaces directly with consumers to validate longevity products and gather market feedback, serving as an early commercial proof point for portfolio technologies.
• Pre-seed and Seed Longevity Venture Fund Early-stage venture capital fund that invests patient capital into pre-seed and seed startups developing therapeutics, platforms and tools, data and AI, and prevention technologies that target the root causes of aging. Includes scientific diligence, KOL support, and access to the fund's clinical and consumer platform infrastructure.

Quantifiable outcome

• 220% increase in global longevity investment to $8.49 billion in 2024
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Emerging players

• NewLimit: Sam Altman–backed longevity biotech developing epigenetic reprogramming therapies. Operates in the same therapeutic modalities Longevitytech.fund invests in but as a single company rather than a fund.
• Retro Biosciences: Longevity biotech startup backed by Sam Altman with $180M raised, focused on cellular reprogramming and autophagy. Comparable in therapeutic focus but operates as a single well-capitalized company rather than a fund.

Direct peers

• Kizoo Technology Ventures: Berlin-based venture firm focused on rejuvenation biotech and longevity startups. One of the longest-running dedicated longevity VCs in Europe; directly comparable mission, stage, and portfolio approach.
• Apollo Ventures: Longevity-focused venture fund backing early-stage companies targeting the biology of aging. Direct peer in asset class, stage, and scientific orientation.
• Longevity Vision Fund: Longevity-focused venture fund investing in early-stage healthspan companies globally — direct competitor for longevity deal flow, LPs, and scientific talent. Same asset class, same stage focus.
• Cambrian Biopharma: Longevity-focused biotech holding company building a distributed pipeline of aging therapeutics. Overlapping thesis (target root causes of aging) and overlapping portfolio modalities (senolytics, mitochondrial).
• Methuselah Fund: Venture fund associated with the Methuselah Foundation, focused on accelerating longevity and rejuvenation biotechnology. Direct peer in mission and portfolio composition.

Broad incumbents

• Flagship Pioneering: Biotech creation engine behind companies like Moderna; increasingly active in longevity and programmable biology. Overlaps in thematic scope but operates with much larger capital base and company-creation model.
• ARCH Venture Partners: Large, established biotech-focused VC that has backed longevity and aging-related companies. Overlaps with Longevitytech.fund's portfolio space but at broader scale and later stages.
• Hevolution Foundation: Saudi-backed non-profit foundation committing $1B+/year to longevity R&D and venture investments globally. Operates at far larger scale than typical specialist funds, providing grants and equity capital across the same sector.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments50 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Longevitytech.fund